References
- ResnikoffSPascoliniDEtya’aleDGlobal data on visual impairment in the year 2002Bull World Health Organ20048284485115640920
- GordonMOBeiserJABrandtJDThe Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open-angle glaucomaArch Ophthalmol200212071472012049575
- BurrJMMowattGHernandezRThe clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: A systematic review and economic evaluationHealth Technol Assess20071141iiiivixx1190
- ChauhanBCMikelbergFSBalasziAGLeBlancRPLeskMRTropeGECanadian Glaucoma Study: Risk factors for the progression of open-angle glaucomaArch Ophthalmol20081261030103618695095
- Collaborative Normal-Tension Glaucoma Study GroupComparison of glaucomatous progression between untreated patients with normaltension glaucoma and patients with therapeutically reduced intraocular pressuresAm J Ophthalmol19981264874979780093
- HeijlALeskeMCBengtssonBHymanLBengtssonBHusseinMReduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma TrialArch Ophthalmol20021201268127912365904
- KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary openangle glaucomaArch Ophthalmol200212070171312049574
- LichterPRMuschDCGillespieBWInterim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgeryOphthalmology20011081943195311713061
- European Glaucoma SocietyTerminology and Guidelines for Glaucoma3rd edSavona, ItalyEditrice, Dogma2008
- ChraiSSMakoidMCEriksenSPRobinsonJRDrop size and initial dosing frequency problems of topically applied ophthalmic drugsJ Pharm Sci1974633333384820359
- PatelSCSpaethGLCompliance in patients prescribed eyedrops for glaucomaOphthalmic Surg1995262332367651690
- DunkerSSchmuckerAMaierHTolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timololAdv Ther20072437638617565929
- BrandtJDCantorLBKatzLJBatoosinghALChouCBossowskaIBimatoprost/timolol fixed combination: A 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma20081721121618414107
- HommerAA double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertensionEur J Ophthalmol200717536217294383
- LimKSNauCBO’ByrneMMMechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover studyOphthalmology200811579079518452763
- SkorkovskaKComparison of intraocular pressure lowering efficacy of bimatoprost/timolol fixed combination and other glaucoma medications in the treatment of glaucomaCesk Slov Oftalmol200864144148 Czech18780653
- ZafarAA switch to bimatoprost/timolol fixed combination resulted in improved IOP reduction in patients with POAG, regardless of previous IOP-lowering therapyPresented at: World Glaucoma CongressBoston, MAJuly 8–11, 2009
- FeuerhakeCBuchholzPKimmichFEfficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: Multicenter, open-label observational studyCurr Med Res Opin2009251037104319290780